UK Markets close in 3 hrs 8 mins

Altimmune, Inc. (0A4C.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
5.01-0.32 (-6.00%)
As of 02:59PM BST. Market open.
Sign in to post a message.
  • L
    LeftyT
    So the Lily CEO is on Squawk this morning talking about their obesity program and stellar P3 results. He projects the sales of this one product to hit $4 BILLION/yr over the next few years. So I pull up the data from the trial and compare it to data from 801 and what do I find? 801 doesn't require dose titration, and has lower AE levels, and has equal or better weight loss in a shorter period of time.

    I wonder what 801 would be worth to someone like Pfizer or J&J in this blockbuster category???
  • P
    Patrick
    Up 34% over the last 5 days low of $3.85. I’m sold my 1,500 shares today. GLTUA.
  • s
    stockpicker
    This stock is a screaming buy. Market cap less than cash in bank. Data for weight loss and clearance of fatty liver in 12 week trial was amazing. P2 results later this year.
  • F
    Ferit
    complete clearance of liver fat, 10% weight loss, almost no side effects. Exactly what the industry wants. J&J failed at the side effects.
  • P
    Patrick
    I can’t believe it, but, I bought 500 @$4.95 today.
  • G
    George
    Hold has to be or not be the trend. Who’s accumulating may get the jackpot. Whatever anything may happen. Let’s hope for the best.
  • A
    Abraham
    (LABP) $0.63 / MCap $26 m / Cash $73 m / has HUGE late stage pipeline --IPO was at $16 last year = Great Reboundplay here with a tgt of 10 dollars ...GL
    https://static.seekingalpha.com/uploads/2021/1/29/saupload_FVuhKb92aIl9d8NORFvgJlzyS61Yroic6x4Yh9BdxYKkAfBq3IKb2C4Nvot2in4BSQvktROM0ZCo68kHzoyox1g3WClOKDTL0zu3-7Fq-yF4Dd-HMFrRo9t-pqWW8L1S6vKiMrVh.jpeg

    ---
  • C
    Chetan
    What is going on with ALT?
  • Y
    Yahoo Finance Insights
    Altimmune reached a 52 Week low at 4.38
  • Z
    Zut
    What’s up with the increase today?
  • Y
    Yahoo Finance Insights
    Altimmune reached a 52 Week low at 4.16
  • P
    Patrick
    Buehler? Buehler? Buehler? Is anyone even following ALT anymore? I no longer own but still read news etc.
  • Z
    Zut
    There’s only 2 viewing!
  • G
    Guido
    Do you ever get tired of being down after good news.
  • U
    UDY
    Who is still investing in the Snake Oil company. They did all the tricks during Covid and made a ton of money. By all means stay away from this junk and save your money. There are 2800+ stocks available in the market.
  • A
    Austin
    B.Riley Sees Increasing Certainty for Secondary COVID Players Novavax (NVAX) and Altimmune (ALT)

    April 16, 2021 7:30 AM
    B.Riley analyst Mayank Mamtani reiterated Buy ratings on Novavax (NASDAQ: NVAX) and Altimmune (NASDAQ: ALT) on the belief that there is increasing certainty around development-stage C-19 vaccine candidates on the heels of the two key recent updates from EUA-approved C-19 vaccines: 1) Johnson & Johnson's (NYSE: JNJ) C-19 vaccine rollout pause on 4/13 within the U.S. recommended by FDA and CDC based on safety concerns, and 2) Moderna's (NASDAQ: MRNA) Vaccines Day on 4/14 suggesting longer development and regulatory timeframes to mimic those of influenza.
    The analyst believes that Novavax is the "only formidable first wave alternative to mRNA vaccines; remain aggressive buyers into imminent Ph. III U.S./Mexico trial data as well as ensuing global regulatory filings." He also "adjusted FCFF by a revenue-weighted approval probability factor that estimates the probability of each of Novavax's vaccine candidates gaining regulatory approval: 75% for Ph. III-stage NanoFlu and 90% for Ph. III-stage NVX-CoV2373, anticipating accelerated approval (EUA) in the mid 2Q time frame."

    Altimmune "limits adenoviral vector exposure to nasal tract; fast approaching Ph. I readout to validate differentiated safety and immunogenicity profile. Recall, AdCOVID is an adenovirus-vectored vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein delivered intranasally with preclinical data suggesting generation of robust IgG-mediated systemic nAbs response and IgA-mediated mucosal immune response."
    For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.
  • B
    Ben
    An article mentions Altimune in the WSJ today. "Next Generation of Covid-19 Vaccines Could Be Pill or Spray." Nice to see a little publicity.

    "The next generation of Covid-19 vaccines in development could come as a pill or a nasal spray and be easier to store and transport than the current handful of shots that form the backbone of the world-wide vaccination effort.

    These newer vaccines, from U.S. government labs and companies including Sanofi SA, Altimmune Inc. and Gritstone Oncology Inc., also have the potential to provide longer-lasting immune responses and be more potent against newer and multiple viral variants, possibly helping to head off future pandemics, the companies say."
  • L
    LeftyT
    If you missed the Jefferies call today, do yourself a favor and go to the Events section of their web site and listen to it. The body language was extremely positive and responses to questions were very confident and clear.

    I believe that AdCovid will become the best in class vaccine for pediatric indications due to their safety profile (comparable to placebo) and ability to totally eliminate viral transmission (key for in school return to normal). Results are on track for later this month, and manufacturing capabilities are being built up with 50 M dose first year capacity expected.

    801 safety profile and tolerability continues to be better than competition, and positive data is expected later this month. They also expect to file a separate IND on Obesity indication once they have the P1 data in hand, which will DOUBLE the value of the 801 program.

    Lot's of good stuff here... so don't miss out.

    AdCovid: Safety comparable to placebo
  • d
    dga
    GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID, a novel, single-dose, intranasal COVID-19 vaccine candidate. Altimmune expects to commence patient enrollment in the Phase 1 clinical trial in the coming week.
  • S
    Sean
    This latest scientific finding just published in Cell, a top-tier journal, demonstrates thoroughly that a single dose of an adenoviral intranasal vaccine (similar to ALT) works much better than intramuscular dosing as it generates full protection in mice while also inducing a strong CD8 T cell response. CD8 T cells are now known to be crucial for generating long term immunity in humans. I'll remind you also that Moderna's vaccine did not elicit any CD8 T cell responses.

    While this data is from an Washington University (who are not making a vaccine for humans) and not ALT, it sets the ALT approach of intranasal vaccine delivery of adenoviral vectors apart from their competitors who are all using intramuscular dosing approaches (apart from VXRT with their tablet). Bullish!

    https://www.sciencedirect.com/science/article/pii/S0092867420310680
    The Coronavirus Disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a …
    The Coronavirus Disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a …
    www.sciencedirect.com